about
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsGLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependenceEffects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgeryGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesTissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequencesPostprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence?A physiologic role for somatostatin 28 as a regulator of insulin secretionEffects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15.Incretin mimetics as emerging treatments for type 2 diabetes.Dumping syndrome: pathophysiology and treatment.Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation.Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?Gut hormones in glucose homeostasis.Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretinsContributions of fat and protein to the incretin effect of a mixed meal.Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.Leptin constrains acetylcholine-induced insulin secretion from pancreatic islets of ob/ob mice.In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.Insulin contributes to fine-tuning of the pancreatic beta-cell response to glucagon-like peptide-1.Oral and intestinal sweet and fat tasting: impact of receptor polymorphisms and dietary modulation for metabolic disease.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Polymeric gene delivery for diabetic treatment.Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats.Effects of CCK on pancreatic function and morphology.Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis.Nutrient-induced secretion and metabolic effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.The influence of body weight, age and glucose tolerance on the relationship between GIP secretion and beta-cell function in man.Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity.Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.Increases in intestinal glucose absorption and hepatic glucose uptake elicited by luminal but not vascular glutamine in the jointly perfused small intestine and liver of the rat.Novel gastroinsular axis involving a gastric transmural glucose flux and vagal mediation.Reduction of incretin-like salivatin in saliva from patients with type 2 diabetes and in parotid glands of streptozotocin-diabetic BALB/c mice.Localization of inhibins and activins in normal endocrine cells and endocrine tumors of the gut and pancreas: an immunohistochemical and in situ hybridization study.
P2860
Q26823085-CD79217C-226C-4E71-8969-20933CC80E17Q26858990-297A6911-5197-4E58-883D-5F840A980DF1Q26995145-B02A963A-18EB-4867-B72D-5F4199E18D0CQ28067465-DC475F16-ECDC-48E9-B6EC-1E5BDBCD9BA9Q28306665-E01D2200-B128-4240-B8D5-00654AA241ACQ28579516-12EE2D5E-3BF6-4A14-B86D-411E5D5724F2Q33194892-8E5DF8E8-877C-446C-A08B-A7829FCB0225Q33789529-3B63993F-D3F5-4250-A8DB-D969ED829644Q35814265-9BCE234E-229F-4A9D-8114-011F80660FB7Q35843905-8B4844BF-FD7B-4E06-A60B-86D0BAD3DAC7Q35962037-5FD1E604-4E4E-496D-AE14-9C5ED5B05E90Q36278454-07572574-F8A5-4904-AF16-D3B3FB3D07D8Q36642535-54E316D5-8D64-4B7A-9FC2-6106F621EB65Q36783856-885035ED-7E4D-4778-A809-110B3865300BQ36902183-9267512A-91BE-45EF-A070-0786009BF785Q37039925-7490F97E-9C55-4943-BA20-58EAA6B59E9DQ37091579-286A9E65-0E46-4077-BC67-DF4F9603A576Q37092070-8EFAE33C-CB9B-4BDA-9401-D5DCCCC6969CQ37351161-E33B0880-2609-4B2D-A35F-3B300D4AEE4CQ37371856-0FBBCEB5-6303-4756-A76B-8988C360248FQ37412882-1B55758B-4D75-4D72-8468-727D9452BFA3Q37941683-1BC7CA95-BD42-4086-8DBD-A4C6553A7073Q38200704-AF2486E8-00DB-4785-9F80-23D86E12A8DAQ38218639-2EBBB29D-3AB8-48AC-BBC5-7170EF324AECQ38470563-767C5747-2E26-4A06-A8F6-0932155800E4Q38503042-8943ACBD-58DC-4252-89A8-336A861725F1Q38527885-DA51139C-2C46-4F88-BF28-617159052950Q38546372-7631C731-1C9A-4C16-B71A-0C4DEA65244FQ40146456-BA1D2687-6952-4E35-839F-F6561FEE5882Q40753264-A72E306A-74FC-4A27-ACE6-ECCD4D7CD603Q41017372-BEC74EE8-5CFF-48C1-BD68-F0F98E4DE89CQ41082128-9F8C0DF5-7950-4FEC-9C62-53609A79B1D3Q41131972-7FDF6D51-9D57-4ECD-BF03-A9354CA81B37Q41294213-8738320C-FCEF-4A84-A11B-0F8D2E11D358Q42488086-B3F00090-BE47-4290-9881-65354AE8D3AAQ42490547-E6B6B778-0C33-495B-B086-516049FD80E2Q42793363-36389515-DE57-474B-AF4A-FE5BE9FA91EAQ43664568-1508ABBD-D059-4D7F-9AA9-6DDF86CDDA79Q43718273-1B4A7F27-1DE3-4547-A2DB-742F6DC6C945Q44733059-D9535F9E-358F-4BED-9F17-B4F3460F0699
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
New developments in the incretin concept.
@en
New developments in the incretin concept.
@nl
type
label
New developments in the incretin concept.
@en
New developments in the incretin concept.
@nl
prefLabel
New developments in the incretin concept.
@en
New developments in the incretin concept.
@nl
P2860
P356
P1433
P1476
New developments in the incretin concept.
@en
P2093
W Creutzfeldt
P2860
P2888
P304
P356
10.1007/BF00281990
P577
1985-08-01T00:00:00Z